241 related articles for article (PubMed ID: 31441943)
1. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
Epperla N; Hamadani M; Reljic T; Kharfan-Dabaja MA; Savani BN; Kumar A
Cancer; 2019 Dec; 125(24):4417-4425. PubMed ID: 31441943
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
[TBL] [Abstract][Full Text] [Related]
4. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
[TBL] [Abstract][Full Text] [Related]
5. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Fitoussi O; Belhadj K; Mounier N; Parrens M; Tilly H; Salles G; Feugier P; Ferme C; Ysebaert L; Gabarre J; Herbrecht R; Janvier M; Van Den Neste E; Morschhauser F; Casasnovas O; Ghesquieres H; Anglaret B; Brechignac S; Haioun C; Gisselbrecht C
Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
[TBL] [Abstract][Full Text] [Related]
6. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
[TBL] [Abstract][Full Text] [Related]
7. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
8. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
9. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.
Ma SY; Tian XP; Cai J; Zhong GZ; Chen X; Huang HQ; Lin TY; Li ZM; Cai QQ
Ann Hematol; 2020 Jun; 99(6):1311-1319. PubMed ID: 32285160
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
11. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
12. Updated Results of Rituximab Pre- and Post-BEAM with or without
Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
[No Abstract] [Full Text] [Related]
13. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
[TBL] [Abstract][Full Text] [Related]
15. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.
Madsen C; Pedersen MB; Vase MØ; Bendix K; Møller MB; Johansen P; Jensen BA; Jensen P; Munksgaard L; Brown PD; Segel EK; d'Amore FA
Ann Oncol; 2015 Feb; 26(2):393-9. PubMed ID: 25411416
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T; Fukuda T; Okumura H; Sunami K; Sawazaki A; Maeda Y; Tsurumi H; Uike N; Hidaka T; Takatsuka Y; Eto T; Tsuda H; Fujisaki T; Miyamoto T; Tsuneyoshi N; Iyama S; Nagafuji K; Harada M
Int J Hematol; 2016 Jun; 103(6):676-85. PubMed ID: 27084252
[TBL] [Abstract][Full Text] [Related]
18. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
19. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
20. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
